azadiradione and Disease-Models--Animal

azadiradione has been researched along with Disease-Models--Animal* in 3 studies

Other Studies

3 other study(ies) available for azadiradione and Disease-Models--Animal

ArticleYear
Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.
    Molecular neurobiology, 2018, Volume: 55, Issue:8

    Huntington's disease (HD) is an autosomal dominantly inherited neurodegenerative disorder caused by expansion of CAG repeats in the coding area of huntingtin gene. In the HD brain, mutant huntingtin protein goes through proteolysis, and its amino-terminal portion consisting of polyglutamine repeats accumulate as inclusions that result in progressive impairment of cellular protein quality control system. Here, we demonstrate that partial rescue of the defective protein quality control in HD model mouse by azadiradione (a bioactive limonoids found in the seed of Azadirachta indica) could potentially improve the disease pathology. Prolonged treatment of azadiradione to HD mice significantly improved the progressive deterioration in body weight, motor functioning along with extension of lifespan. Azadiradione-treated HD mice brain also exhibited considerable decrease in mutant huntingtin aggregates load and improvement of striatal pathology in comparison with age-matched saline-treated HD controls. Biochemical analysis further revealed upregulation and activation of not only HSF1 (master regulator of protein folding) but also Ube3a (an ubiquitin ligase involved in the clearance of mutant huntingtin) in azadiradione-treated mice. Our results indicate that azadiradione-mediated enhanced folding and clearance of mutant huntingtin might underlie improved disease pathology in HD mice and suggests that it could be a potential therapeutic molecule to delay the progression of HD.

    Topics: Animals; Atrophy; Disease Models, Animal; Disease Progression; Dopamine and cAMP-Regulated Phosphoprotein 32; Heat Shock Transcription Factors; Huntingtin Protein; Huntington Disease; Limonins; Longevity; Mice, Transgenic; Models, Biological; Motor Activity; Mutant Proteins; Neostriatum; Protein Aggregates; Quality Control; Ubiquitin-Protein Ligases; Up-Regulation

2018
Azadiradione ameliorates polyglutamine expansion disease in Drosophila by potentiating DNA binding activity of heat shock factor 1.
    Oncotarget, 2016, Nov-29, Volume: 7, Issue:48

    Aggregation of proteins with the expansion of polyglutamine tracts in the brain underlies progressive genetic neurodegenerative diseases (NDs) like Huntington's disease and spinocerebellar ataxias (SCA). An insensitive cellular proteotoxic stress response to non-native protein oligomers is common in such conditions. Indeed, upregulation of heat shock factor 1 (HSF1) function and its target protein chaperone expression has shown promising results in animal models of NDs. Using an HSF1 sensitive cell based reporter screening, we have isolated azadiradione (AZD) from the methanolic extract of seeds of Azadirachta indica, a plant known for its multifarious medicinal properties. We show that AZD ameliorates toxicity due to protein aggregation in cell and fly models of polyglutamine expansion diseases to a great extent. All these effects are correlated with activation of HSF1 function and expression of its target protein chaperone genes. Notably, HSF1 activation by AZD is independent of cellular HSP90 or proteasome function. Furthermore, we show that AZD directly interacts with purified human HSF1 with high specificity, and facilitates binding of HSF1 to its recognition sequence with higher affinity. These unique findings qualify AZD as an ideal lead molecule for consideration for drug development against NDs that affect millions worldwide.

    Topics: Animals; Azadirachta; Disease Models, Animal; DNA; Dose-Response Relationship, Drug; Drosophila melanogaster; Drosophila Proteins; HCT116 Cells; Heat Shock Transcription Factors; HEK293 Cells; Humans; Limonins; Neurodegenerative Diseases; Neuroprotective Agents; Peptides; Plant Extracts; Protein Aggregation, Pathological; Protein Binding; Seeds; Time Factors; Transfection

2016
Cytoprotective and Anti-secretory Effects of Azadiradione Isolated from the Seeds of Azadirachta indica (neem) on Gastric Ulcers in Rat Models.
    Phytotherapy research : PTR, 2015, Volume: 29, Issue:6

    Azadirachta indica is well known medicinal plant mentioned in ancient herbal texts. It has been extensively used in Ayurvedic, Unani and Homoeopathic medicine and has become a luminary of modern medicine. As part of our drug discovery program we isolated azadiradione from the ethanolic extract of seeds of A. indica and evaluated for in-vivo antiulcer activity in cold restraint induced gastric ulcer model, aspirin induced gastric ulcer model, alcohol induced gastric ulcers model and pyloric ligation induced ulcer model. Azadiradione exhibited potent antiulcer activity through the inhibition of H+ K+-ATPase (proton pump) activity via its cytoprotective effect and also via its antisecretory effect. This combined effect has valuable potential in the future treatment of peptic ulceration.

    Topics: Animals; Anti-Ulcer Agents; Azadirachta; Dinoprostone; Disease Models, Animal; Female; Limonins; Male; Plant Extracts; Plants, Medicinal; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Seeds; Stomach Ulcer

2015